Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Anbio Biotechnology Class A Ordinary Shares stock (NNNN) is currently trading at $23.76. Anbio Biotechnology Class A Ordinary Shares PE ratio is 392.33. Anbio Biotechnology Class A Ordinary Shares PS ratio (Price-to-Sales) is 149.30. WallStSmart rates NNNN as Sell.
- NNNN PE ratio analysis and historical PE chart
- NNNN PS ratio (Price-to-Sales) history and trend
- NNNN intrinsic value — DCF, Graham Number, EPV models
- NNNN stock price prediction 2025 2026 2027 2028 2029 2030
- NNNN fair value vs current price
- NNNN insider transactions and insider buying
- Is NNNN undervalued or overvalued?
- Anbio Biotechnology Class A Ordinary Shares financial analysis — revenue, earnings, cash flow
- NNNN Piotroski F-Score and Altman Z-Score
- NNNN analyst price target and Smart Rating
Anbio Biotechnology Class A
📊 No data available
Try selecting a different time range
NNNN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Anbio Biotechnology Class A Ordinary Shares (NNNN)
NNNN trades 3894% above its Graham fair value of $0.68, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Anbio Biotechnology Class A Ordinary Shares (NNNN) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, profit margin. Concerns around price/sales and price/book. Mixed signals suggest waiting for clearer direction before acting.
Anbio Biotechnology Class A Ordinary Shares (NNNN) Key Strengths (2)
Keeps $74 of every $100 in revenue after operating costs
Keeps $37 of every $100 in revenue as net profit
Anbio Biotechnology Class A Ordinary Shares (NNNN) Areas to Watch (7)
Revenue declining -21.60%, a shrinking business
Very expensive at 149.3x annual revenue
Very expensive at 36.4x book value
Earnings barely growing at 2.80%
Very low institutional interest at 4.85%
Small-cap company with higher risk but more growth potential
Moderate profitability with room for improvement
Supporting Valuation Data
Anbio Biotechnology Class A Ordinary Shares (NNNN) Detailed Analysis Report
Overall Assessment
This company scores 37/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Profit Margin. Profitability is solid with Operating Margin at 73.50%, Profit Margin at 37.20%.
The Bear Case
The primary concerns are Revenue Growth, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (149.30), Price/Book (36.38) suggest expensive pricing. Growth concerns include Revenue Growth at -21.60%, EPS Growth at 2.80%, which may limit upside. Profitability pressure is visible in Return on Equity at 11.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 11.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -21.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Revenue Growth and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NNNN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NNNN's Price-to-Sales ratio of 149.30x sits near its historical average of 132.74x (63th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 45% below its historical high of 271.44x set in Jul 2025, and 326% above its historical low of 35.02x in Apr 2025. Over the past 12 months, the PS ratio has expanded from ~40.5x, reflecting growing market expectations outpacing revenue growth.
Compare NNNN with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Anbio Biotechnology Class A Ordinary Shares (NNNN) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Anbio Biotechnology Class A Ordinary Shares faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 7M with 22% decline year-over-year. Profit margins are strong at 37.2%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 1120.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 37.2% and operating margin of 73.5% demonstrate strong pricing power and operational efficiency.
Revenue contracted 22% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Valuation compression risk at a P/E of 392.3x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Anbio Biotechnology Class A Ordinary Shares.
Bottom Line
Anbio Biotechnology Class A Ordinary Shares faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Anbio Biotechnology Class A Ordinary Shares(NNNN)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.